Sanofi (SNY)

Sanofi files a 20-F with the SEC once a year, in euros. In the year to 31 December 2025 it reported revenue from the sale of goods of EUR 43,626 million, up 6.2% on the year before. Its profit attributable to shareholders was EUR 7,813 million, up 40.5%, and diluted earnings per share EUR 6.37.

Earnings per share are per ordinary share, in euros. The share that trades in the US can be a depositary share standing for more or fewer ordinary shares, so no price ratio is worked out on this page.

The public record on SNY

Profit and loss, 11 fiscal years

EUR million, from each year's annual report on the SEC's EDGAR, the year linked to its filing, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated. A year marked * shows the figure as the company restated it in a later annual report (Dec 2017, Dec 2019, Dec 2020, Dec 2022, Dec 2023); the first-filed figure is in the CSV. Profit for the year includes the part that belongs to minority shareholders; profit attributable to shareholders is the part EPS is struck on.

EUR per ordinary share, as filed.

Cash flow

EUR million. Purchase of property, plant and equipment is the cash line as filed; purchases of intangible assets and acquisitions are not in it. Free cash flow is cash from operations less that purchase, arithmetic on the two filed lines.

Balance sheet at year end

EUR million, at each fiscal year end. Borrowings is the company's own stated total where it files one; it is never added up from its parts here.

Ratios on the filed lines

Arithmetic on the filed lines of the same year: margins over revenue, return on equity as profit attributable to shareholders over year-end equity, tax over profit before tax.

Annual reports on EDGAR